Bristol Myers Squibb and Johnson & Johnson

New Capabilities

Jointly developing milvexian, a rival Factor XIa inhibitor

Roughly a quarter of the 795,000 Americans who have a stroke each year have had one before. On Monday the Food and Drug Administration approved Sunharbo, a daily pill from Bayer that cuts the risk of a second ischemic stroke by 26% when taken alongside existing antiplatelet therapy.

Updated 2 hours ago